Highlighted Sessions



Cecilia McGough
Students with Schizophrenia

Click for Bio

Cecilia McGough is a mental health advocate, activist, writer, media consultant, and radio astronomer located in the United States. Cecilia also happens to have schizophrenia but does not let it define her. Cecilia is the founder and executive director of the nonprofit Students With Schizophrenia. Cecilia is the blogger/vlogger for the I Am Not A Monster: Schizophrenia project, a TED speaker with over 3 million views on YouTube and a Special Books By Special Kids interviewee with over 12 million views on Facebook. In addition, Cecilia is an UNLEASH talent who traveled to Denmark in August of 2017 to be an active voice towards attaining the United Nations’ Sustainable Development Goals (SDGs).

Cecilia was the founder and president of the Penn State Pulsar Search Collaboratory. She had participated in pulsar research continuously since December of 2009 until December 2017 while co-discovering pulsar J1930-1852 at the age of 17 with the widest orbit ever observed around another neutron star. A pulsar is a super dense neutron star which emits dipole electromagnetic radiation. Cecilia was a Virginia Aerospace Science and Technology Scholar through the NASA Langley Research Center and the Virginia Space Grant Consortium. She competed in the International Space Olympics held in Russia and was named "Miss Space Olympics 2012.” Cecilia is listed as a co-author for her pulsar research through the Pulsar Search Collaboratory in the Astrophysics Journal: arXiv:1503.06276v1. It is Cecilia McGough’s personal mission to help ensure a day where no one worldwide is afraid to say the words "I have schizophrenia.” Together, we can change the face of schizophrenia, and Students With Schizophrenia is apart of that solution.


Brandon Staglin
One Mind

Click for Bio

As President of One Mind, Brandon Staglin channels his deep experience in communications, advocacy, and personal schizophrenia recovery to drive brain health research programs to heal lives. Brandon served as Director of Marketing and Communications for One Mind Institute from 2005 to 2017, and as a Board Director for One Mind Institute and One Mind from 2015 to 2017. Brandon also serves on advisory councils for the National Institute of Mental Health, the California Mental Health Services Authority’s Help@Hand Program, Mindstrong Health, and Stanford University’s Prodrome and Early Psychosis Program Network, and is a member of The Stability Network. He earned a Master of Science in Healthcare Administration and Interprofessional Leadership from UCSF in September 2018, and Bachelor of Arts degrees in Engineering Sciences and Anthropology from Dartmouth College in 1993.

Among Brandon’s recent work, he has successfully advocated for the growth of data-driven, networked, continuously improving prevention and early intervention services for youth facing serious psychiatric illness. He has originated One Mind’s ASPIRe program, which aims to dramatically increase both quality treatment access and recovery rates for such individuals through expanding and improving early care. His work was instrumental in the passage of California laws AB 1315 and SB 1004, providing funding and accountability for such services statewide.

Brandon has received numerous awards for his brain health advocacy, including the Lifetime Achievement VOICE Award from the U.S. Substance Abuse and Mental Health Services Administration, the Clifford W. Beers Award from Mental Health America, the Shattering Stigma—Realizing Recovery Award from the Schizophrenia and Related Disorders Alliance of America, and the Clifford W. Beers Centennial Service Award from the Clifford W. Beers Clinic.

Brandon’s lived experience with recovery from schizophrenia makes him grateful to be living in health and happy every day he can contribute to the health of others.


Computational Approaches to Understand Psychosis

Tiago Maia
Computational Psychiatry

Click for Bio

Tiago V. Maia is an Associate Professor at the Faculty of Medicine of the University of Lisbon (Portugal). He did his Ph.D. in Psychology at Carnegie Mellon University. Before returning to Portugal (his home country), he was an Assistant Professor of Clinical Neurobiology in the Department of Psychiatry at Columbia University. Research in his laboratory focuses on the integrated use of computational modeling, brain imaging, and behavioral experiments to understand the neural bases of several psychiatric disorders. His work has been published in several leading journals (e.g., Nature Neuroscience and PNAS). He has also played an active role in the development and promotion of the emerging field of computational psychiatry (e.g., serving as guest editor or guest co-editor for special issues on the topic for Biological Psychiatry, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, and Clinical Psychological Science). He was considered a “Rising Star” by the Association for Psychological Science.

Andreas Meyer-Lindenberg
A.I./Computational Approaches

Click for Bio

Prof. Meyer-Lindenberg is Director of the Central Institute of Mental Health and Head of the Executive Board, as well as the Medical Director of the Department of Psychiatry and Psychotherapy at the Institute, based in Mannheim, Germany, and Professor and Chairman of Psychiatry and Psychotherapy at the University of Heidelberg in Heidelberg, Germany. He is board certified in psychiatry, psychotherapy, and neurology. Before coming to Mannheim in 2007, he spent ten years as a scientist at the National Institutes of Mental Health, Bethesda, USA. Prof. Meyer-Lindenberg is the author of more than 300 peer-reviewed articles and book chapters in journals such as Nature, Science, Nature Neuroscience, Nature Medicine, Nature Reviews Neuroscience, Nature Genetics, Neuron, PNAS, and others. He is has been continuously named as one of the most highly cited scientists in the world (www.isihighlycited.com) He is the Editor-in-Chief of the European Journal of Neuropsychopharmacology, associate editor of Science Advances and on the editorial board of a number of other journals such as Schizophrenia Bulletin, European Neuropsychopharmacology, Psychiatry Research: Neuroimaging, and Neuroimage.

His research interests focus on the development of novel treatments for severe psychiatric disorders, especially schizophrenia, through an application of multimodal neuroimaging, genetics and enviromics to characterize brain circuits underlying the risk for mental illness and cognitive dysfunction.

In recognition of his research, Prof. Meyer-Lindenberg has received awards throughout his career, including: Bristol-Myers-Squibb Young Investigator Award (1998), NIH Award for Excellence in Biomedical Research (1999,2000,2001), NARSAD Young Investigator Award (2000), Department of Health and Human Services Secretary’s Award for Distinguished Service (2006), Roche/Nature Medicine Award for Translational Neuroscience (2006), the Joel Elkes International Award for Clinical Research from the American College of Neuropsychopharmacology (2006), A.E. Bennett Award of the Society for Biological Psychiatry (2007), NARSAD Distinguished Investigator Award (2009), Kurt Schneider Scientific Award (2010), the Hans-Jörg Weitbrecht-Preis für Klinische Neurowissenschaften (2011), the ECNP Neuropsychopharmacology Award (2012), the Prix ROGER DE SPOELBERCH (2014), and the 2016 CINP Lilly Neuroscience Clinical Research Award.

Kerstin Ritter
From Machine to Deep Learning in Clinical Neuroimaging

Click for Bio

Kerstin Ritter is a junior professor for Computational Neuroscience and leads the group "Machine Learning in Clinical Neuroimaging" at the Department of Psychiatry and Psychotherapy at Charité - Universitätsmedizin Berlin. Trained as a mathematician, she did her PhD at the Bernstein Center for Computational Neuroscience Berlin (2012). From 2013 to 2015, she was responsible for multimodal data integration within the framework of the EU-funded joint project "Integrative Decision Support System for different types of dementia". Since October 2017, she holds a Rahel-Hirsch scholarship and is P.I. in the GRF-funded project “Deep learning for neuroimaging-based disease decoding”. In 2018, she was awarded a NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation (USA) for "Studying mental health via research domain criteria, neuroimaging and convolutional neural networks". In 2019, she got two further grants in order to predict disease activity in patients with multiple sclerosis (DMSG and EDMUS). Her expertise lies at the intersection of artificial intelligence (explainable machine/deep learning), neuroimaging and neurological/psychiatric diseases (e.g. multiple sclerosis, Alzheimer's disease or schizophrenia).

Current State of Treatment of First Episode Psychosis

Merete Nordentoft
Treatment of First Episode of Psychosis

Click for Bio

Merete Nordentoft is an expert in epidemiology, suicidal behavior, psychopathology and a pioneer in early intervention in psychosis. She was PI for many large randomized clinical trials, evaluating the effect of psychosocial intervention, of which the Danish OPUS trial (specialized assertive intervention in first episode psychosis) is the most well known. 

She has worked with suicide prevention at a national level since 1997. Together with a group of epidemiologist from Nordic countries, she has proved that life expectancy in schizophrenia is 15 to 20 years shorter than in the general population.

She is involved as one of the PI’s in iPSYCH, the Lundbeck Foundation Initiative for Integrative Psychiatric Research, which aims at investigating genetic and environmental causes of mental disorders. The initiation of the large Danish High Risk and Resilience Study VIA 7, and the first follow-up wave VIA 11 are important parts of iPSYCH.

She was given the prestigious award “Global Excellence in Health” in 2012 and in 2016. She received the Richard Wyatt Award in 2016, The Marie and August Krogh Award in 2017, and The Danish Medical Association’s Honorific Award in 2018.

Genetics and Personalized Treatment

Cynthia Shannon Weickert
Genetics and Personalized Treatment

Click for Bio

Prof Shannon Weickert earned a PhD in Biomedical Science from Mount Sinai Medical School in New York City. She spent the next 11 years in the Intramural Research program at the National Institute of Mental Health (NIMH) in Washington DC. In 2006, she became a Professor of Psychiatry at the University of New South Wales in Sydney, Australia, and in 2017, a Professor of Neuroscience and Physiology at Upstate Medical University, in Syracuse New York. Prof Shannon Weickert is the NSW Chair of Schizophrenia Research and is a National Health and Medical Research Council (Australia) Principal Research Fellow.

For over 30 years, Prof Shannon Weickert has focused her research on determining the biological basis of schizophrenia. She is a molecular biologist and neuroanatomist by training and has used these skills to discover blunted neuronal plasticity, increased neuroinflammation, and hormonal receptor disturbances in the brains of people with schizophrenia. Her expertise as a cellular neurobiologist and experience in cortical histology, anatomical molecular mapping, transcriptomics, and quantitative molecular assays in human brain and blood has led to the identification of an inflammatory biotype of schizophrenia characterized by elevations in cytokines.

Prof Shannon Weickert has made seminal contributions to the conceptualization of schizophrenia as a disorder of neuronal plasticity, and is best known for her pioneering studies on pathways that regulate neocortical growth and maturation in people with schizophrenia (her BDNF paper being cited >500 times). She has led studies that identified the birthplace of neurons in the postnatal human brain and other studies demonstrating that the postnatal recruitment of cortical inhibitory neurons is robust in humans and is likely abnormal in schizophrenia. She leads a translational research program at Neuroscience Research Australia (NeuRA) aimed at discovering the molecular and cellular underpinnings of schizophrenia in order to translate these discoveries into novel treatments for people with schizophrenia through the design and implementation of investigator initiated clinical trials.

Prof Shannon Weickert has over 234 papers, often publishing in high-ranking journals such as Molecular Psychiatry, Archives of General Psychiatry, Biological Psychiatry, Neuropsychopharmacology, Schizophrenia Bulletin and Journal of Neuroinflammation. She has a total of 15010 cites and an h-index of 70.

In 2015, Prof Shannon Weickert was awarded the competitive Nina Kondelos Prize by the Australian Neuroscience Society, which is awarded to an outstanding female neuroscientist. In 2016 she was awarded the Biological Psychiatry Australia (BPA) Isaac Schweitzer Award. She was also honoured in 2016 by being promoted to Fellow Member of the prestigious American College of Neuropsychopharmacology (ACNP).

Daniel Mueller
Genetics and Personalized Treatment

Click for Bio

Dr. Mueller earned his MD at the University of Bonn (Germany) and completed his residency training at the Charité University Clinic in Berlin. He has then been appointed as Professor at the University of Toronto (Departments of Psychiatry and Pharmacology), and as Clinician Scientist at the Centre for Addiction and Mental Health (CAMH) in Toronto since 2008. He is Head of the Pharmacogenetics Research Clinic at CAMH which is one of the first of its kind worldwide to implement pharmacogenetics in clinical practice for antidepressant and antipsychotic medications.

Throughout his career, his overall research goals are to investigate genetic causes of response and side effects to psychiatric medications on which he published more than 200 articles. This line of research aims to significantly improve treatment of psychiatric conditions and to lessen the burden of medication side effects and to avoid adverse drug-drug interactions. In addition, he is actively involved in developing pharmacogenetics treatment recommendations for physicians and patients through his close collaboration with the Clinical Pharmacogenetics Implementation Consortium.

Adrienne Lahti
Genetics and Personalized Treatment

Click for Bio

Adrienne C. Lahti, M.D. is a board certified psychiatrist, the F. Cleveland Kinney Professor and the Vice Chair for Research Training and Faculty Development in the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham (UAB). She directs the Division of Behavioral Neurobiology and leads the Neuroimaging and Translational Research Laboratory. For the past 25 years, she has used brain imaging techniques such as Positron Emission Tomography (PET), functional MRI (fMRI), MR Spectroscopy (MRS), and Diffusion Tensor Imaging (DTI) to study the pathophysiology of schizophrenia and evaluate the effects of various psychotropic drugs on brain function and biochemistry.

Debate on the Concept of Clinical

Frauke Schultze-Lutter
Debate on the Concept of Clinical

Click for Bio

Since 04/2017, Frauke Schultze-Lutter works as a Senior Researcher at the LVR-Klinikum Düsseldorf and Associate Professor at the Medical Faculty of the Heinrich-Heine University Düsseldorf, Germany. She is head of the research unit “Early Detection” and of the early detection and intervention (EDI) services of the departments of both adult (PP) and child and adolescent psychiatry and psychotherapy (CAPP). Before, she was Associate Professor at the University of Bern where, for the last 18 months, she was Acting Director of the Research Department of the University Hospital of Child and Adolescent Psychiatry and Psychotherapy. During her work in Bern from 2009-2017, she also established and led the common early detection and intervention service of the University Psychiatric Hospital Bern (both PP and CAPP) and the Soteria Bern. Before, in 1998, she had initiated and, until 2009, lead Europe’s first EDI service (FETZ) at the PP of the University of Cologne, Germany.

Working in the field of EDI since 1994, she is an internationally recognized expert in this field and, for more than 10 years, is providing training and supervision in the assessment of clinical high risk of psychosis. Within the SPI study funded by the German Research Foundation (DFG), she developed an early detection instrument for adults that, so far, is available in 8 languages (incl. Portuguese), and later on, for children and adolescents (currently available in 3 languages). Besides more than 100 original publications in high impact international journals, she is main author of the European Psychiatric Association’s (EPA) guidance on the early detection of psychosis and second author of the of the European Psychiatric Association’s (EPA) guidance on the early intervention in clinical high risk states of psychosis. She is also well experienced in epidemiological studies on clinical high risk in children, adolescents and adults and led two projects on these topics funded by the Swiss National Science Foundation (SNF).

Sinan Guloksuz
Debate on the Concept of Clinical
Click for Bio

Dr. Guloksuz is an Assistant Professor of Psychiatry at the Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, and Adjunct Assistant Clinical Professor of Psychiatry at the Department of Psychiatry, Specialized Treatment Early in Psychosis (STEP) Program, Yale University School of Medicine. He earned his MD degree from Gazi University, Turkey, and MSc and PhD degrees from Maastricht University, the Netherlands. His PhD project investigated the biological mechanisms of environmental stressors in psychosis, with a particular focus on the immune system. He is a proud alumnus of the psychiatry training program at Bakirkoy Research and Training Hospital for Psychiatry, Neurology, and Neurosurgery, Istanbul, Turkey. With a background in clinical psychiatry and translational epidemiology, Dr. Guloksuz’s broader research focus has been on understanding the mechanisms underlying psychosis spectrum disorder and testing gene and environment theories at the convergence of multidimensional psychopathology in epidemiological studies.

Daniel Mathalon
Debate on the Concept of Clinical

Click for Bio

Daniel Mathalon, Ph.D., M.D. is a Professor and Deputy Vice-Chair for Research in the Department of Psychiatry at the University of California, San Francisco. He directs the Path Program for Early Psychosis at UCSF and the Brain Imaging and EEG Laboratory located at the San Francisco VA Medical Center, where he also serves as Chief of General Psychiatric Outpatient Services.  Dr. Mathalon received a B.A. in Psychology from U.C. Berkeley, a Ph.D. in Psychology from Indiana University, and an M.D. from Stanford University.  He completed his psychiatric residency training and a research fellowship in Psychophysiology at Stanford University.  Following this training, he joined the Department of Psychiatry at Yale University, and after 8 years, he moved to his lab to UCSF.  Dr. Mathalon uses EEG and MRI based methods to study brain dysfunction in neuropsychiatric disorders, particularly schizophrenia.  A major focus of his work has been to identify neurophysiological biomarkers of risk for psychosis among individuals meeting criteria for the psychosis risk syndrome.  In support of this work, Dr. Mathalon serves as the principal investigator for the UCSF site in the multi-site North American Psychosis-Risk Longitudinal Study (NAPLS 3).  Current efforts are focused on examining abnormalities in neural plasticity as a basis for gray matter loss and neurocognitive impairments in schizophrenia.

Dual Diagnosis

Eden Evins
Dual Diagnosis: Tobacco

Click for Bio

Dr. A. Eden Evins is founder and director of the Center for Addiction Medicine at Massachusetts General Hospital, and The Cox Family Professor of Psychiatry in the Field of Addiction Medicine at Harvard Medical School.

Dr. Evins earned her undergraduate degree at the University of Virginia and her medical degree at the Medical University of South Carolina in Charleston. She completed an internship in Pediatric Medicine at the Children’s National Medical Center in Washington DC and her residency in psychiatry at Massachusetts Mental Health Center and Harvard-Longwood Psychiatry Residency Training Program in Boston, where she was also chief resident. She conducted a fellowship in molecular biology at the Mailman Research Center of McLean Hospital and a second fellowship in clinical and translational research at MGH with Dr. Don Goff. She received a Master’s in Public Health in Clinical Effectiveness from the Harvard School of Public Health.

Dr. Evins studies of efficacy of pharmacotherapeutic cessation aids in smokers with and without serious mental illness, of the effect of nicotine on cognitive performance in those with and without schizophrenia, of behavioral, physiologic and fMRI ascertained assessments of impulsivity, risk taking, reactivity to drug-related cues and the relationship between cue reactivity and relapse to drug use, and effect of cannabis on psychiatric symptoms, cognitive function, and addictive behaviors. She has conducted a series of studies that have changed clinical practice guidelines for smoking cessation for those with serious mental illness. Dr. Evins has extensive ties with Community Health Centers that have made it possible to conduct large clinical and implementation studies. She has been PI of a 10-site multi-center study conducted in community mental health centers across 6 US states and PI of a PCORI Large Pragmatic Trial that enrolled over 1100 tobacco smokers with serious mental illness in Greater Boston.

Dr. Evins has received two career awards from the National Institute on Drug Abuse (NIDA) of the National Institute of Health (NIH), has twice received a National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD) Young Investigator Award, received the National Institute for Mental Health (NIMH) New Clinical Drug Evaluation Unit Young Investigator Award, and the Massachusetts Department of Public Health Tobacco Control Program Young Investigator Award. She has mentored over 35 junior investigators, many with K awards, has authored well over 100 publications, including over 50 publications with a mentee as first author.

Eva Hoch
Dual Diagnosis: Cannabis

Click for Bio

Dr. Hoch has an international reputation as researcher in the field of cannabis and cannabinoids. She is a lecturer and lead psychologist at the Department of Psychiatry, Ludwig-Maximilian University, Munich (Germany). As researcher, she is the head of the Cannabinoid Research and Treatment Group.

Dr. Hoch was honored through different research awards, e.g. the distinguished Wilhelm-Feuerlein Award in clinical addiction research (2017). Her most recent work focuses on risks and health benefits of cannabinoids.

Further information:

Gabriele Fischer
Dual Diagnosis: Opiates

Click for Bio

Gabriele Fischer is medical director of the Addiction Clinic, Department of Psychiatry & Psychotherapy, MUV, where substance use disorders and non-substance dependent patients (e.g. pathological gamblers) are treated in addition to a variety of research programs, with a double-assignment to the Center for Public Health. As a scientist she has more than 140 peer-reviewed scientific publications and is consultant of WHO & UN and board member of the scientific committee of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). G. Fischer has been involved in comprehensive international research co-operations and is a member of multiple international scientific associations.

Psychotherapy for Psychosis

Philippa Garety
Developments and Challenges in Digital Therapies for Psychosis

Click for Bio

Philippa Garety is Professor of Clinical Psychology at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King’s College London and a consultant clinical psychologist at the South London & Maudsley NHS Foundation Trust. 

Philippa’s research has focussed on the investigation of cognitive and emotional processes in in psychosis, particularly delusions and hallucinations, together with psychological therapy and service development.  Her work has aimed to translate the findings of research into improvements in treatments and service provision for people with psychosis.  She has published extensively on Cognitive Behavioural Therapy for Psychosis and led a series of influential randomised controlled trials of this approach. Most recently she has led research programmes developing and evaluating psychological interventions which make novel use of digital technology to enhance psychosis treatment, including SlowMo for Paranoia and AVATAR therapy for distressing voices. 

Philippa was awarded the Shapiro achievement award in 2002 for eminence in clinical psychology by the British Psychology Society and in 2007 was selected as a Senior Investigator of the UK National Institute of Health Research, and is now Senior Investigator emerita. She has recently been awarded the 2018 British Psychological Society lifetime achievement award.

Farooq Naeem
Culturally Adapted CBT for Psychosis

Click for Bio

Dr. Farooq Naeem is a Professor of Psychiatry at the University of Toronto and staff psychiatrist in Schizophrenia Program, Center for Addiction and Mental Health, Toronto, Canada. He was trained in Psychiatry in Merseyside training scheme in Liverpool, England. He completed his MSc in Research Methods in Health and PhD at the Southampton University in England. He also received training in Lean thinking and in quality improvement in England. He has pioneered techniques for culturally adapting CBT. These techniques have been used to adapt CBT for a variety of common and severe mental health problems in South Asia, North Africa, the Middle East, China, England and Canada. He has nearly 200 publications, including; peer-reviewed journals articles, books and book chapters . He has presented his work at numerous conferences, and has conducted many workshops globally. His research areas include CBT, psychosis and culture, with an overall aim to improve access to CBT. He works with a team of IT experts, and has developed a CBT-based therapy program – called eGuru – that can be delivered through web and smart phone apps.

Brandon Gaudiano
ACT for Schizophrenia

Click for Bio

Brandon Gaudiano, Ph.D. is a clinical psychologist and researcher at Butler Hospital in Providence, Rhode Island.  He holds appointments as Associate Professor in the Department of Psychiatry and Human Behavior at the Warren Alpert Medical School of Brown University, and in the Department of Behavioral and Social Sciences at the School of Public Health. At Butler Hospital, he develops and directs transitional outpatient programming, focusing on treatment delivery for patients across levels of care (e.g., inpatient to outpatient). Dr. Gaudiano’s research has been supported by grant funding from the National Institutes of Health, Department of Veterans Affairs, and other private foundations (American Foundation for Suicide Prevention) for conducting treatment research in individuals with various forms of severe mental illness, including psychosis, severe mood disorders, suicidal behaviors, and comorbid substance use. He also is a Senior Investigator in the Mindfulness Center at Brown University, where he studies novel acceptance/mindfulness-based interventions, including applications for individuals with psychosis. In 2105, he published a book titled Incorporating Acceptance and Mindfulness into the Treatment of Psychosis by Oxford University Press.  In addition, Dr. Gaudiano has served in editorial roles for several scientific journals in psychiatry and psychology. He currently chairs the Publications Committee of the American Psychology Association (APA) for Division 12 (Clinical Psychology), and recently was appointed to the APA’s Advisory Steering Committee on Clinical Practice Guidelines, which oversees the process of guideline development.

Steffen Moritz

Click for Bio

Prof. Dr. Steffen Moritz is professor of clinical psychology and head of the Clinical Neuropsychology Unit at the University Medical Center Hamburg-Eppendorf (Germany). He has developed a number of self-help interventions and treatment programs for psychosis, obsessive-compulsive disorder and depression that are available at no cost via www.clinical-neuropsychology.de. He is author of over 200 research articles.

Using Mobile Technology to Enhance Treatment and Research in Psychosis

Justin Baker
Passive Sensing Using App for Treatment and Predictive Outcomes

Click for Bio

Justin T. Baker, MD, PhD, is the scientific director of the McLean Institute for Technology in Psychiatry and the director of Functional Neuroimaging and Bioinformatics for the Schizophrenia and Bipolar Disorder Research Program at McLean Hospital. His research uses both large scale studies and deep phenotyping approaches to understand the nature and underlying biology of mental illnesses, particularly lifelong conditions like schizophrenia and bipolar disorder.

Assistant Professor of Psychiatry
Director of Functional Neuroimaging & Bioinformatics 
Schizophrenia and Bipolar Disorder Program
Scientific Director, Institute for Technology in Psychiatry
McLean Hospital
Harvard Medical School

Inez Myin-Germeys
Experience Sampling in Understanding the Emotional Lives of Individuals with Psychosis

Click for Bio

Inez Myin-Germeys is a psychologist and professor of Contextual Psychiatry at KU Leuven, Belgium. She is the head of the Center for Contextual Psychiatry (CCP), which she founded in 2015 at KU Leuven in Belgium. Prof. Inez Myin-Germeys is a world-renowned expert in the field of Experience Sampling Methodology and mobile Health (mHealth). Within the CCP, the main research lines are 1) the further methodological and statistical development of ESM research, 2) the study of psychological processes in related to psychopathology as they occur in real life, 3) the clinical implementation of ESM, 4) the development of Ecological Momentary Interventions, and 5) qualitative research and research from a first-person perspective. Inez Myin-Germeys has published over 350 papers and has supervised over 30 PhD projects.

Tara Niendam
Mobile Health Platforms for Clinical Monitoring in Early Psychosis

Click for Bio

Dr. Niendam is an Associate Professor in Psychiatry and a licensed clinical psychologist. She obtained a B.A. in Psychology from Northwestern University and Ph.D. in Clinical Psychology from the University of California, Los Angeles. As the Executive Director of the UC Davis Early Psychosis Programs (EDAPT and SacEDAPT Clinics), Dr. Niendam supervises clinic and training activities, and coordinates outreach and educational presentations within Sacramento and across California. She has developed 4 early psychosis programs in Northern California based on the coordinated specialty care model of early psychosis, sharing expertise on the course of early psychotic illness, evidenced based treatments for psychosis, and the use of standardized clinical assessments of early psychosis symptoms, functioning, and outcomes. She serves as the Co-Director for a pre-doctoral Trauma and Adolescent Mental Illness (TAMI) internship, which aims to provide trauma-integrated cognitive behavioral therapy (TI-CBTp) to youth with early psychosis.

Overall, her research focuses on improving clinical and functional outcomes for youth with serious mental illness across four key themes: 1) Elucidating factors that contribute to real world functioning and clinical outcome across psychiatric disorders, 2) Evaluating the impact of interventions on outcomes in psychosis, 3) Developing technology-enhanced methods to improve identification and enhance treatment, and 4) Dissemination of best practices for early psychosis care.  With prior funding from the Robert Wood Johnson Foundation and UC Davis Behavioral Health Center of Excellence, she developed and tested a technology enhanced data collection platform in multiple community based clinics, demonstrating how data can be used to enhance EP care in community settings. As a Co-I on an NIMH-funded project to reduce the duration of untreated psychosis in Sacramento, she led the creation and implementation of a tablet-based app to screen for early psychosis in community settings to support rapid referral to care.

Neil Thomas
Digitally Assisted Therapy for Psychosis

Click for Bio

Associate Professor Neil Thomas is Director of the National eTherapy Centre and Deputy Director of the Centre for Mental Health at Swinburne University of Technology in Melbourne, Australia. He leads the PERISCOPE Lab conducting a research program on developing self-management interventions, with an emphasis on both interventions for psychosis and therapeutic applications of digital technology.

Originally training in clinical psychology in the UK, Neil went on to specialise in psychological treatments with the Maudsley Hospital. After moving to Melbourne he set up a specialist Voices Clinic providing psychological interventions for hallucinations, and became a leader in intervention research for people who hear voices. He later moved into digital mental health, leading an Australian government-funded digital mental health service for high prevalence disorders, in parallel to Victorian state government funded research examining the role of digital technology in service delivery for people with severe mental illness. He has trialled a variety of digital interventions spanning web-based self-management courses, ecological momentary assessment and intervention, virtual reality, and telehealth.

Wordpress Social Share Plugin powered by Ultimatelysocial